<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878783</url>
  </required_header>
  <id_info>
    <org_study_id>URomLS2022</org_study_id>
    <nct_id>NCT04878783</nct_id>
  </id_info>
  <brief_title>RADIOMICS AND MOLECULAR EXPRESSION PREDICTIVE MODEL FOR ESOPHAGO-GASTRIC JUNCTION AND GASTRIC CANCER TRG</brief_title>
  <official_title>CT SCAN-BASED RADIOMICS AND MOLECULAR EXPRESSION PREDICTIVE MODEL TO ASSESS TUMOR REGRESSION GRADE FOLLOWING PERIOPERATIVE CHEMOTHERAPY IN ESOPHAGO-GASTRIC JUNCTION AND GASTRIC CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Andrea Laghi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to develop a CT scan-based radiomics predictive model about tumor&#xD;
      regression grade (TRG) in patients with esophago-gastric junction (EGJ) ang gastric cancer&#xD;
      undergoing perioperative chemotherapy. The molecular expression of the neoplasms will be&#xD;
      evaluated to assess its association with the TRG and the radiomic features.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      • To compare the radiomic features of the CT scans at the time of diagnosis (T0) and at the&#xD;
      end of the preoperative chemotherapy (T1) in order to predict the TRG with the texture&#xD;
      analysis on the first CT scan.&#xD;
&#xD;
      A non-good response (non-GR) has shown to be predictable with texture analysis on the&#xD;
      pre-treatment CT scan.&#xD;
&#xD;
      Therefore, we hypothesize that texture analysis could let to identify the good response&#xD;
      patients.&#xD;
&#xD;
      • To find correlation between the molecular expression of the tumor and the radiomics&#xD;
      features.&#xD;
&#xD;
      Texture analysis on the pre-chemotherapy CT scan founded that entropy and compactness were&#xD;
      higher and uniformity lower in responders. Nonetheless the association between radiomics&#xD;
      features and molecular expression has not been investigated yet.&#xD;
&#xD;
      Therefore, we hypothesize to add some others radiomics signatures to the analysis and to find&#xD;
      an association with the molecular expression.&#xD;
&#xD;
      • To find correlation between the molecular expression of the tumor and the TRG.&#xD;
&#xD;
      MSI gastric cancer has been shown to be less responsive to preoperative chemotherapy.&#xD;
&#xD;
      Therefore, we hypothesize to confirm this result.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">December 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Predictive performance of radiomics analysis on the pre-treatment CT scan.</measure>
    <time_frame>2 months</time_frame>
    <description>Comparing the radiomic features of the CT scans at the time of diagnosis (T0) and at the end of the preoperative chemotherapy (T1) in order to predict the TRG with the texture analysis on the first CT scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of the radiomics features with the molecular expression of the tumor.</measure>
    <time_frame>2 months</time_frame>
    <description>Texture analysis on the pre-chemotherapy CT scan founded that entropy and compactness were higher and uniformity lower in responders. Nonetheless the association between radiomics features and molecular expression has not been investigated yet.&#xD;
Therefore, we hypothesize to add some others radiomics signatures to the analysis and to find an association with the molecular expression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the association between TRG and the molecular expression of the tumor.</measure>
    <time_frame>2 months</time_frame>
    <description>Investigate if the molecular expression of the tumor can influence the TRG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between radiomics and molecular expression in regards to long-term outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Analysis of the 3 and 5y DFS and OS of patients with the radiomics and molecular expression profile</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Adenocarcinoma of the Stomach</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT scan</intervention_name>
    <description>Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study</description>
    <other_name>FLOT chemotherapy</other_name>
    <other_name>Radical Gastrectomy with D2 Lymphadenectomy</other_name>
    <other_name>Radical Esophagogastrectomy with D2 Lymphadenectomy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Gastrectomy or esophagogastrectomy specimen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cT2-T4a, cN0-N3, M0 gastric or EGJ cancer who undergo FLOT perioperative&#xD;
        chemotherapy followed by radical surgical resection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven adenocarcinoma of the EGJ (Siewert II-III) or&#xD;
             stomach.&#xD;
&#xD;
          -  Preoperative staging: cT2-T4a, cN0-N3, M0.&#xD;
&#xD;
          -  Patients &gt;18 years old.&#xD;
&#xD;
          -  Patients undergoing perioperative chemotherapy with Docetaxel, oxaliplatin,&#xD;
             leucovorin, and 5-fluorouracil (FLOT).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Siewert I EGJ tumor&#xD;
&#xD;
          -  Patients undergoing preoperative radiotherapy.&#xD;
&#xD;
          -  Absence of both pre and post-chemotherapy CT-scan.&#xD;
&#xD;
          -  Patients with tumor progression during preoperative chemotherapy.&#xD;
&#xD;
          -  Patients undergoing other neoadjuvant chemotherapy regimen different from FLOT&#xD;
&#xD;
          -  Exploratory laparoscopy with positive cytology on the peritoneal lavage or evidence of&#xD;
             peritoneal carcinosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Giovanni M GARBARINO, M.D</last_name>
    <phone>+393334693359</phone>
    <email>giovannimaria.garbarino@uniroma1.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Giovanni Maria Garbarino</name>
      <address>
        <city>Roma</city>
        <zip>00191</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>giovanni m garbarino, M.D.</last_name>
      <phone>+393334693359</phone>
      <email>giovannimaria.garbarino@uniroma1.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Giovanni Maria Garbarino</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>radiomics</keyword>
  <keyword>molecular expression</keyword>
  <keyword>perioperative chemotherapy</keyword>
  <keyword>FLOT</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>esophago-gastric junction cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

